Orchestra BioMed Holdings (OBIO) FCF Margin (2022 - 2026)
Orchestra BioMed Holdings' (OBIO) quarterly FCF Margin came in at 20320.0% in Q1 2026, down 1839281.0% year-on-year from N/an in Q1 2025, and down 266439.43% on a QoQ basis from 7.62% in Q4 2025.
Orchestra BioMed Holdings (OBIO) FCF Margin (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has 5 years of FCF Margin data on file, last reported at 20320.0% in Q1 2026.
- On a quarterly basis, FCF Margin fell 1839281.0% year-over-year to 20320.0% in Q1 2026; TTM through Mar 2026 was 167.33%, a 171947.0% increase from a year earlier, with the FY2025 full-year figure at 146.74%, up 178074.0% from the prior year.
- FCF Margin for Q1 2026 stood at 20320.0%, down from 7.62% in the prior quarter.
- Over the last five years, FCF Margin for OBIO reached as high as 7.62% in Q4 2025 and fell as low as 20320.0% in Q1 2026.
- Historically, FCF Margin has averaged 2892.7% across 5 years, with a median of 1682.46% in 2025.
- Across the five-year window, FCF Margin surged 538526 bps in 2025 and slumped 1839281 bps in 2026, its largest moves.
- Year by year, FCF Margin stood at 797.64% in 2022, then plunged by 425 bps to 4187.4% in 2023, then slipped by 29 bps to 5392.89% in 2024, then jumped by 100 bps to 7.62% in 2025, then sank by 266439 bps to 20320.0% in 2026.
- Per Business Quant data, the three most recent FCF Margin figures were 20320.0% in Q1 2026, 7.62% in Q4 2025, and 1682.46% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Orchestra BioMed Holdings | 235.83 Mn | 141.43 Mn | 78,000.00 | -20,320.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20,320.00% |
| Dec 31, 2025 | -7.62% |
| Sep 30, 2025 | -1,682.46% |
| Jun 30, 2025 | -1,861.36% |
| Mar 31, 2025 | -1,927.19% |
| Dec 31, 2024 | -5,392.89% |
| Sep 30, 2024 | -1,394.93% |
| Jun 30, 2024 | -1,325.58% |
| Mar 31, 2024 | -2,116.45% |
| Dec 31, 2023 | -4,187.40% |
| Sep 30, 2023 | -2,458.47% |
| Jun 30, 2023 | -1,149.40% |
| Mar 31, 2023 | -1,238.49% |
| Dec 31, 2022 | -797.64% |
| Sep 30, 2022 | -643.16% |
| Jun 30, 2022 | -2,052.62% |
| Mar 31, 2022 | -620.21% |